Philadelphia, Pennsylvania--(Newsfile Corp. - January 3, 2025) - Current Edwards Lifesciences (NYSE: EW) shareholders who have held shares of the Company's stock since prior to February 6, 2024, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more at https://grabarlaw.com/the-latest/edwards-shareholder-investigation/, email Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.
Why: A recently filed federal securities fraud class action was filed against Edwards Lifesciences (NYSE: EW) and three of its officers, in which it is alleged that Defendants provided investors with materially false and misleading information concerning Edwards' expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company's core product, Transcatheter Aortic Valve Replacement ("TAVR"). Defendants' statements included, among other things, strong commitment to the TAVR platform, confidence in the Company's ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets.
The underlying securities fraud complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Edwards' TAVR platform; notably, that the Company's claims and confidence relied far too heavily on their perceived ability to engage the claimed low-treatment rate population of patients and an overestimation of the desire for hospitals and other care facilities to continue to utilize and otherwise commit resources to the TAVR procedures over newer, innovative treatment alternatives.
On July 24, 2024 the truth emerged when Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. Investors and analysts reacted immediately to Edwards' revelations and the price of Edwards' common stock declined dramatically.
What You Can Do: Current Edwards Lifesciences shareholders who have held shares of the Company's stock since prior to February 6, 2024, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.
If you would like to learn more at no cost to you, please visit https://grabarlaw.com/the-latest/edwards-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or Mia Heller at mheller@grabarlaw.com, or call us at 267-507-6085.
Attorney Advertising Disclaimer
$EW #EW #EdwardsLifesciences
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235986
